PROS1 and COVID-19: From the results of these studies, we hypothesize that when treating patients positive for COVID-19, the active components of QFDYG, such as saikosaponins and glycyrrhizic acid, may enter cells infected with SARS-CoV-2, bind to membrane proteins, such as the S protein, regulate various pathways resulting in an anti-viral effect.